Technical Program
*Note: This schedule is preliminary and is subject to change*
Thursday, September 20th |
|
8:30 AM - 12:00 PM | REGISTRATION |
9:30 AM - 9:40 AM | WELCOMING REMARKS |
9:40 AM - 10:25 AM | KEYNOTE SPEAKER: Pathology from the Molecular Scale on Up Garry Nolan, Stanford University |
10:25 AM - 11:25 AM | SESSION 1: CD19 STORY: WHAT HAS WORKED, AND LESSONS LEARNED FROM THE SUCCESS OF CAR T CELL THERAPY |
10:25 AM - 10:55 AM |
INVITED SPEAKER: Defined Composition CD19 CAR-T cells for Adult B cell Malignancies Cameron Turtle, Fred Hutchinson Cancer Research Center |
10:55 AM - 11:10 AM |
Tales of Three CAR T Cell Start-Ups Ronald Dudek, Lentigen Technology, Inc. |
11:10 AM - 11:25 AM |
Systematic Investigation of Parameters That Affect In Vivo CAR-T Cell Function Ximin Chen, University of California, Los Angeles |
11:25 AM - 11:55 AM | BREAK |
11:55 AM - 1:40 PM | SESSION 2: CHALLENGES AND OPPORTUNITIES FOR CELL THERAPIES FOR SOLID TUMORS (ANTIGENS, METABOLISM, AND THE TUMOR MICROENVIRONMENT) |
11:55 AM - 12:25 PM |
INVITED SPEAKER: Genetic Engineering Approaches to Improve CAR T Cell Anti-Tumor Activity for Solid Tumors Giedre Krenciute, St. Jude Childrens Research Hospital |
12:25 PM - 12:55 PM |
INVITED SPEAKER: Signal Control of CD8 T Cell Immune Responses Xiaoping Zhong, Duke University School of Medicine |
12:55 PM - 1:10 PM |
Macrophage-Mediated Delivery of Light Activated Nitric Oxide Prodrugs with Spatial, Temporal and Concentration Control Michael A. Evans, Harvard University |
1:10 PM - 1:25 PM |
Tumor Cell Intrinsic Factors Dictate Immune Cell Infiltration and Response to Immunotherapy Katelyn T. Byrne, Parker Institute for Cancer Immunotherapy |
1:25 PM - 1:40 PM |
Self-Cancellation Mechanism of the PD-L1/PD-1 Pathway Enfu Hui, University of California, San Diego |
1:40 PM - 2:45 PM | LUNCH |
2:45 PM - 3:15 PM | SESSION 3: GENOME EDITING FOR THERAPEUTIC CELL ENGINEERING: EFFICACY VS SAFETY |
2:45 PM - 3:15 PM |
INVITED SPEAKER: Reprogramming Human T Cell Circuitry Alexander Marson, University of California, San Francisco |
3:15 PM - 4:30 PM | SESSION 4: INDUSTRY PANEL |
3:15 PM - 4:30 PM |
Justin Farlow, Co-Founder and CTO, Serotiny, Inc. Julie Norville, Co-Founder, JURA Bio, Inc. Elizabeth Wood, Co-Founder, JURA Bio, Inc. |
4:30 PM - 6:00 PM | Poster Session and Networking Reception |
Friday, September 21st |
|
8:00 AM - 12:00 PM | REGISTRATION |
8:45 AM - 8:50 AM | OPENING REMARKS |
8:50 AM - 9:35 AM |
KEYNOTE SPEAKER: Translation of YESCARTA庐, a first-in-class CAR T cell product for Non-Hodgkin Lymphoma Adrian Bot, Kite Pharma |
9:35 AM - 11:50 AM | SESSION 5: IMMUNOTHERAPY: IMMUNE CELLS OTHER THAN CONVENTIONAL T CELLS |
9:35 AM - 10:05 AM |
INVITED SPEAKER: Manipulating Tregs to Control Tolerance in Autoimmunity and Cancer Qizhi Tang, University of California, San Francisco |
10:05 AM - 10:35 AM |
INVITED SPEAKER: Immunoengineering for Improved Antitumor Immunity Michael Goldberg, Dana-Farber Cancer Institute |
10:35 AM - 11:05 AM | BREAK |
11:05 AM - 11:20 AM |
In Vivo Metabolic Labeling and Targeted Modulation of Dendritic Cells for Enhanced Cancer Immunotherapy Hua Wang, Harvard University |
11:20 AM - 11:35 AM |
Lentiviral-mediated FOXP3 gene transfer to convert CD4+ T cells to Treg cells: a suitable method for immunotherapy Rosa Bacchetta, Stanford University |
11:35 AM - 11:50 AM |
Generation of Antigen-Specific Germinal Center-like B Cells As a Next-Generation Immunotherapy Hannah Song, Georgia Institute of Technology |
11:50 AM - 12:35 PM | SESSION 6: TCR T CELLS |
11:50 PM - 12:20 PM |
INVITED SPEAKER: Adoptive Cell Therapy: Enabling Technologies for Endogenous T Cell (ETC) Therapy of Cancer Cassian Yee, MD Anderson Cancer Center |
12:20 PM - 12:35 PM |
Novel Engineering Approaches for Developing Therapeutically Relevant T Cell Receptors for Use in T Cell Therapies for Multiple Sclerosis (MS) Elissa Leonard, University of Texas at Austin |
12:35 PM - 2:00 PM | LUNCH |
2:00 PM - 3:30 PM | SESSION 7: NOVEL DELIVERY TECHNOLOGY FOR CELL THERAPIES |
2:00 PM - 2:30 PM |
INVITED SPEAKER: Enhancing T cell Immunotherapy Using Responsive Biomaterials Li Tang, 脡cole polytechnique f茅d茅rale de Lausanne (EPFL) |
2:30 PM - 3:00 PM |
INVITED SPEAKER: In Situ Programming of Therapeutic T Cells Using Synthetic Nanoparticles Matthias Stephan, University of Washingto, Seattle, WA |
3:00 PM - 3:15 PM |
Treating Diabetes with a Cup of Coffee Daniel Bojar, ETH Zurich |
3:15 PM - 3:30 PM |
Single Use Disposable Biosettler Removes the Dead Cells and Cell Debris Selectively to Increase the Viability Percentage of Mammalian Cells (e.g. CAR-T) during Expansion Dhinakar Kompala, Sudhin Biopharma Co |
Saturday, September 22 |
|
7:00 AM - 8:00 AM | REGISTRATION |
8:00 AM - 8:10 AM | OPENING REMARKS |
8:10 AM - 9:55 AM | SESSION 8: UNDERSTANDING AND ENGINEERING PERSISTENCE |
8:10 AM - 8:40 AM |
INVITED SPEAKER: Improving the expansion and persistence of CAR T-cells for solid tumors Cliona Rooney, Baylor College of Medicine |
8:40 AM - 9:10 AM |
INVITED SPEAKER: Towards the development of a dual antigen AND-gate CAR T for prostate cancer Amy Gilbert, Kite Pharma |
9:10 AM - 9:25 AM |
Supervised Machine Learning Methods for Chemometric Modeling and Predicting in Biotherapeutic Manufacturing Processes Thomas Li, Pfizer |
9:25 AM - 9:40 AM |
Decision Tools in the Assistance of the CAR T-Cell Industry Maria Papathanasiou, Imperial College, London |
9:40 AM - 9:55 AM |
Drug Response Landscape of BRAF-Mutated Melanoma Cells: Non-Quiescent "Idling Population State" As an Alternative Drug Persistence Bishal Paudel, Vanderbilt University |
9:55 AM - 10:10 AM |
Functionalized Microcarriers for Enhanced CAR T Cell Manufacturing Nate Dwarshuis, Georgia Institute of Technology |
10:10 AM - 10:25 AM | BREAK |
10:25 AM - 12:15 PM | SESSION 9: SYNTHETIC BIOLOGY FOR CELLULAR IMMUNOTHERAPY |
10:25 AM - 10:55 AM |
INVITED SPEAKER: Engineering the Next Generation of Immune Cell Therapies Kole Roybal, University of California, San Francisco |
10:55 AM - 11:25 AM |
INVITED SPEAKER: Engineering Biological Computers for Human Health Applications Tim Lu, Massachusetts Institute of Technology |
11:25 AM - 11:40 AM |
Synthetic Transcriptional Regulation for Human Cell Therapy Divya Israni, Boston University |
11:40 AM - 11:55 AM |
Design Driven Engineering of Extracellular Sensors for the Development of Mammalian Cell-Based Therapies Taylor Dolberg, Northwestern University |
11:55 AM - 12:10 PM |
Thermal Bioswitches for Noninvasive Control of Cell Function Dan Piraner, California Institute of Technology |
12:10 PM - 12:15 PM | Closing Remarks |